BOSTON SCIENTIFIC CORP — Director's Dealing 2021

Feb 23, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BOSTON SCIENTIFIC CORP (BSX)
CIK: 0000885725
Period of Report: 2021-02-21

Reporting Person: Fitzgerald Joseph Michael (EVP & Pres, Interven Cardio)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-21	Common Stock	M	3894.0000	$0.0000	Acquired	248824.0000	Direct
2021-02-21	Common Stock	F	1922.0000	$38.0300	Disposed	246902.0000	Direct
2021-02-22	Common Stock	M	4056.0000	$0.0000	Acquired	250958.0000	Direct
2021-02-22	Common Stock	F	2002.0000	$39.2000	Disposed	248956.0000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-21	Deferred Stock Units	$	M	3894.0000	Disposed	2023-02-21	Common Stock (3894.0000)	Direct
2021-02-22	Deferred Stock Units	$	M	4056.0000	Disposed	2021-02-22	Common Stock (4056.0000)	Direct
2021-02-22	Performance Share Units	$	A	13134.0000	Acquired	2022-12-31	Common Stock (13134.0000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	68312.0000	Indirect
Common Stock	6038.0000	Indirect

Footnotes

F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2: Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.

F3: The reporting person disclaims beneficial ownership of the shares held by his children, and this report should not be deemed an admission that the reporting person is the beneficial owner of his children's shares for purposes of Section 16 or for any other purpose.

F4: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant.

F5: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.

F6: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F7: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022.